Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02364713
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:51.000514+00:00
Published At
2025-11-17T00:00:00+00:00
Record Updated At
2025-12-11
Results Posted At
2025-11-17
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Clear Cell Adenocarcinoma", "Primary Peritoneal Endometrioid Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-11"
protocolSection.identificationModule.nctId
"NCT02364713"
protocolSection.identificationModule.officialTitle
"MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator\u0027s Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-11-17"

Study condition terms

  • Fallopian Tube Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Seromucinous Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Resistant Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Resistant Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Resistant Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.